

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 - 37. (Cancelled)

38. (Previously Presented) An *in vitro* method of functionally determining at physiological conditions deficiencies in the lectin pathway of the complement system, employing a sample of mammalian blood, serum, plasma, or another body fluid obtained from a mammal, the method comprising the steps of

- (a) adding an C1 complex inhibitor selected from the group consisting of proteins, peptides or immunoglobulins against C1q, C1r or C1s;
- (b) diluting the sample to inhibit the activation of the alternative pathway;
- (c) adding a MBL (mannan-binding lectin) or ficolin binding carbohydrate activating the lectin pathway in the sample;
- (d) adding an first antibody against the autologous C5b-9 complex and
- (e) determining the activation of the lectin pathway at the physiological condition by measuring the autologous C5b-9 complex.

39. (Previously Presented) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, surfactant protein A and HNP-1.

40. (Currently Amended) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of TDGDKAFVDFLSDEIKKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5) and LEQGENVFLQATLL (SEQ ID NO. 6).

41. (Previously Presented) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of polyclonal and monoclonal antibodies.
42. (Previously Presented) The method according to claim 38, wherein the carbohydrate in step (c) is selected from the group consisting of mannose, fucose, mannan such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide.
43. (Previously Presented) The method according to claim 38, wherein the first antibody in step (d) is a polyclonal or a monoclonal antibody.
44. (Previously Presented) The method according to claim 43, wherein the step in (d) comprises adding a second antibody against the first antibody, wherein said second antibody is a labeled antibody.
45. (Previously Presented) The method according to claim 43, wherein the first antibody is a labeled antibody.
46. (Previously Presented) A kit for functionally determining in a body fluid from a mammal deficiencies in the lectin pathway of the complement system, which kit comprises (a) an inert carrier and a MBL or ficolin binding carbohydrate (b) a diluent comprising a C1 complex inhibitor selected from the group consisting of peptides, proteases or immunoglobulins against C1q, C1r or C1s and (c) a first antibody against the autologous C5b-9 complex.
47. (Previously Presented) The kit according to claim 46, wherein the carbohydrate in (a) is selected from the group consisting of mannose, fucose, mannan such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide.
48. (Previously Presented) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding

protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, surfactant protein A and HNP-1.

49. (Currently Amended) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of the peptides, TDGDKAFVDFLSDEIKKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5) and LEQGENVFLQATLL (SEQ ID NO. 6).

50. (Previously Presented) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of polyclonal and monoclonal antibodies.

51. (Previously Presented) The kit according to claim 46, wherein the first antibody in (c) is a polyclonal or monoclonal antibody.

52. (Previously Presented) The kit according to claim 47, wherein the carbohydrate in (a) is coated on the inert carrier.

53. (Previously Presented) The kit according to claim 51, wherein the first antibody in (c) is a labeled antibody.

54. (Previously Presented) The kit according to claim 51, wherein the kit further comprises a labeled second antibody (d) against the antibody in (c).

55. (Previously Presented) The kit according to claim 53, wherein the kit further comprises an enzyme substrate (e).

56. (Previously Presented) The kit according to claims 46, wherein the kit further comprises a washing solution (f).

57. (Previously Presented) The kit according to claim 46, wherein the kit further comprises a normal body liquid from a mammal (g).

58. (Previously Presented) The kit according to claim 57, wherein the normal body liquid (g) is a human serum.

59. (Previously Presented) The kit according to claim 46, wherein the kit further comprises an inactivated normal body liquid from a mammal (h).

60. (Previously Presented) The kit according to claim 59, wherein the inactivated normal body liquid (h) is heat inactivated human serum.